{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:37:26Z","timestamp":1790458646735,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR20COVI0016"],"award-info":[{"award-number":["ANR20COVI0016"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009243","name":"Direction G\u00e9n\u00e9rale de l\u2019offre de Soins","doi-asserted-by":"publisher","award":["COVID-19-20-0004"],"award-info":[{"award-number":["COVID-19-20-0004"]}],"id":[{"id":"10.13039\/501100009243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Severe acute respiratory syndrome coronavirus-2 (SARS\u2013CoV-2)-induced acute respiratory distress syndrome (ARDS) causes high mortality. Umbilical cord-derived mesenchymal stromal cells (UC-MSCs) have potentially relevant immune-modulatory properties, whose place in ARDS treatment is not established. This phase 2b trial was undertaken to assess the efficacy of UC-MSCs in patients with SARS\u2013CoV-2-induced ARDS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This multicentre, double-blind, randomized, placebo-controlled trial (STROMA\u2013CoV-2) recruited adults (\u2265\u200918\u00a0years) with SARS\u2013CoV-2-induced early (&lt;\u200996\u00a0h) mild-to-severe ARDS in 10 French centres. Patients were randomly assigned to receive three intravenous infusions of 10<jats:sup>6<\/jats:sup> UC-MSCs\/kg or placebo (0.9% NaCl) over 5\u00a0days after recruitment. For the modified intention-to-treat population, the primary endpoint was the partial pressure of oxygen to fractional inspired oxygen (PaO<jats:sub>2<\/jats:sub>\/FiO<jats:sub>2<\/jats:sub>)-ratio change between baseline (day (D) 0) and D7.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 107 patients screened for eligibility from April 6, 2020, to October 29, 2020, 45 were enrolled, randomized and analyzed. PaO<jats:sub>2<\/jats:sub>\/FiO<jats:sub>2<\/jats:sub> changes between D0 and D7 did not differ significantly between the UC-MSCs and placebo groups (medians [IQR] 54.3 [\u2212\u200915.5 to 93.3] vs 25.3 [\u2212\u200933.3 to 104.6], respectively; ANCOVA estimated treatment effect 7.4, 95% CI \u2212\u200944.7 to 59.7; <jats:italic>P<\/jats:italic>\u2009=\u20090.77). Six (28.6%) of the 21 UC-MSCs recipients and six of 24 (25%) placebo-group patients experienced serious adverse events, none of which were related to UC-MSCs treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>D0-to-D7 PaO<jats:sub>2<\/jats:sub>\/FiO<jats:sub>2<\/jats:sub> changes for intravenous UC-MSCs-versus placebo-treated adults with SARS\u2013CoV-2-induced ARDS did not differ significantly. Repeated UC-MSCs infusions were not associated with any serious adverse events during treatment or thereafter (until D28). Larger trials enrolling patients earlier during the course of their ARDS are needed to further assess UC-MSCs efficacy in this context.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic>: NCT04333368. Registered 01 April 2020, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/history\/NCT04333368\">https:\/\/clinicaltrials.gov\/ct2\/history\/NCT04333368<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13054-022-03930-4","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:06:53Z","timestamp":1645470413000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9647-7043","authenticated-orcid":false,"given":"Antoine","family":"Monsel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Hauw-Berlemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miryam","family":"Mebarki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Heming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mayaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otriv","family":"Nguekap Tchoumba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Demoule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djillali","family":"Annane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Marois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Demeret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Voiriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Fartoukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Constantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"M\u00e9garbane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebtan","family":"Plantef\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Malard-Castagnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Burrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Rosenzwajg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Tchitchek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Boucher-Pillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Churlaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Cras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Maheux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Pezzana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou Hassimiou","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Ropers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Menasch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Larghero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"APHP STROMA\u2013CoV-2 Collaborative Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9borah","family":"Benchetrit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Bonvallot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Charbonnier-Beaupel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Dhib-Charfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre Romain","family":"Delmotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assitan","family":"Kone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Le Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Puybasset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe-Elie","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Vezinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"3930_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s00134-020-06294-x","volume":"47","author":"COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators","year":"2021","unstructured":"COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2021;47:60\u201373.","journal-title":"Intensive Care Med"},{"key":"3930_CR2","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"WJ Wiersinga","year":"2020","unstructured":"Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782.","journal-title":"JAMA"},{"key":"3930_CR3","doi-asserted-by":"crossref","unstructured":"The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020;324(13):1330\u20131341.","DOI":"10.1001\/jama.2020.17023"},{"key":"3930_CR4","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"The REMAP-CAP Investigators","year":"2021","unstructured":"The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384:1491\u2013502.","journal-title":"N Engl J Med"},{"key":"3930_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13054-020-03449-6","volume":"25","author":"D Contou","year":"2021","unstructured":"Contou D, Fraiss\u00e9 M, Pajot O, Tirolien J-A, Mentec H, Plantef\u00e8ve G. Comparison between first and second wave among critically ill COVID-19 patients admitted to a French ICU: no prognostic improvement during the second wave? Crit Care. 2021;25:3.","journal-title":"Crit Care"},{"key":"3930_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41536-019-0083-6","volume":"4","author":"MF Pittenger","year":"2019","unstructured":"Pittenger MF, Discher DE, P\u00e9ault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. npj Regen Med. 2019;4:22.","journal-title":"npj Regen Med"},{"key":"3930_CR7","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3727\/096368915X689622","volume":"25","author":"T Squillaro","year":"2016","unstructured":"Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016;25:829\u201348.","journal-title":"Cell Transplant"},{"key":"3930_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738697","volume":"12","author":"Z Xu","year":"2021","unstructured":"Xu Z, Huang Y, Zhou J, Deng X, He W, Liu X, et al. Current status of cell-based therapies for COVID-19: evidence from mesenchymal stromal cells in sepsis and ARDS. Front Immunol. 2021;12: 738697.","journal-title":"Front Immunol"},{"key":"3930_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nbt.2816","volume":"32","author":"JA Ankrum","year":"2014","unstructured":"Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014;32:252\u201360.","journal-title":"Nat Biotechnol"},{"key":"3930_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.100249","volume":"19","author":"M Thompson","year":"2020","unstructured":"Thompson M, Mei SHJ, Wolfe D, Champagne J, Fergusson D, Stewart DJ, et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis. EClinicalMedicine. 2020;19: 100249.","journal-title":"EClinicalMedicine"},{"issue":"4","key":"3930_CR11","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.stemcr.2021.01.021","volume":"16","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Ravikumar M, Ling L, Nurcombe V, Cool SM. Age-related changes in the inflammatory status of human mesenchymal stem cells: implications for cell therapy. Stem Cell Reports. 2021;16(4):694\u2013707.","journal-title":"Stem Cell Reports"},{"key":"3930_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S2213-2600(14)70291-7","volume":"3","author":"JG Wilson","year":"2015","unstructured":"Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015;3:24\u201332.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"3930_CR13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S2213-2600(18)30418-1","volume":"7","author":"MA Matthay","year":"2019","unstructured":"Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7(2):154\u201362.","journal-title":"Lancet Respir Med"},{"key":"3930_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1465-9921-15-39","volume":"15","author":"G Zheng","year":"2014","unstructured":"Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res. 2014;15:39.","journal-title":"Respir Res"},{"issue":"12","key":"3930_CR15","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jcyt.2017.08.004","volume":"19","author":"A Can","year":"2017","unstructured":"Can A, Celikkan FT, Cinar O. Umbilical cord mesenchymal stromal cell transplantations: a systemic analysis of clinical trials. Cytotherapy. 2017;19(12):1351\u201382.","journal-title":"Cytotherapy"},{"key":"3930_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/scrt442","volume":"5","author":"PR Amable","year":"2014","unstructured":"Amable PR, Teixeira MVT, Carias RBV, Granjeiro JM, Borojevic R. Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton\u2019s jelly. Stem Cell Res Ther. 2014;5:53.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"3930_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41536-019-0070-y","volume":"16","author":"D Kehl","year":"2019","unstructured":"Kehl D, Generali M, Mallone A, Heller M, Uldry A-C, Cheng P, et al. Proteomic analysis of human mesenchymal stromal cell secretomes: a systematic comparison of the angiogenic potential. NPJ Regen Med. 2019;16(4):8.","journal-title":"NPJ Regen Med"},{"issue":"1","key":"3930_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.retram.2019.09.001","volume":"68","author":"LL Liau","year":"2020","unstructured":"Liau LL, Ruszymah BHI, Ng MH, Law JX. Characteristics and clinical applications of Wharton\u2019s jelly-derived mesenchymal stromal cells. Curr Res Transl Med. 2020;68(1):5\u201316.","journal-title":"Curr Res Transl Med"},{"key":"3930_CR19","doi-asserted-by":"publisher","first-page":"8558","DOI":"10.1111\/jcmm.16817","volume":"25","author":"Y Xie","year":"2021","unstructured":"Xie Y, Chen F, Jia L, Chen R, Zhang VW, Zhong X, et al. Mesenchymal stem cells from different sources show distinct therapeutic effects in hyperoxia-induced bronchopulmonary dysplasia in rats. J Cell Mol Med. 2021;25:8558\u201366.","journal-title":"J Cell Mol Med"},{"key":"3930_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s13287-021-02376-9","volume":"12","author":"R Ciccocioppo","year":"2021","unstructured":"Ciccocioppo R, Gibellini D, Astori G, Bernardi M, Bozza A, Chieregato K, et al. The immune modulatory effects of umbilical cord-derived mesenchymal stromal cells in severe COVID-19 pneumonia. Stem Cell Res Ther. 2021;12:316.","journal-title":"Stem Cell Res Ther"},{"key":"3930_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s12015-020-09973-w","volume":"16","author":"A Golchin","year":"2020","unstructured":"Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal stem cell therapy for COVID-19: present or future. Stem Cell Rev and Rep. 2020;16:427\u201333.","journal-title":"Stem Cell Rev and Rep"},{"issue":"2","key":"3930_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.14336\/AD.2020.0228","volume":"11","author":"Z Leng","year":"2020","unstructured":"Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216\u201328.","journal-title":"Aging Dis"},{"issue":"4","key":"3930_CR23","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/sctm.20-0189","volume":"10","author":"C Desterke","year":"2021","unstructured":"Desterke C, Griscelli F, Imeri J, Marcoux P, Lemonnier T, Latsis T, et al. Molecular investigation of adequate sources of mesenchymal stem cells for cell therapy of COVID-19-associated organ failure. Stem Cells Transl Med. 2021;10(4):568\u201371.","journal-title":"Stem Cells Transl Med"},{"issue":"31","key":"3930_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021429","volume":"99","author":"B Liang","year":"2020","unstructured":"Liang B, Chen J, Li T, Wu H, Yang W, Li Y, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: a case report. Medicine (Baltimore). 2020;99(31): e21429.","journal-title":"Medicine (Baltimore)"},{"key":"3930_CR25","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.2147\/IDR.S272645","volume":"13","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Zhu R, Liu K, Li X, Chen D, Bai D, et al. Human umbilical cord mesenchymal stem cells for adjuvant treatment of a critically ill COVID-19 patient: a case report. Infect Drug Resist. 2020;13:3295\u2013300.","journal-title":"Infect Drug Resist"},{"key":"3930_CR26","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s11684-020-0810-9","volume":"14","author":"L Tang","year":"2020","unstructured":"Tang L, Jiang Y, Zhu M, Chen L, Zhou X, Zhou C, et al. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Front Med. 2020;14:664\u201373.","journal-title":"Front Med"},{"key":"3930_CR27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41392-020-00286-5","volume":"5","author":"F Meng","year":"2020","unstructured":"Meng F, Xu R, Wang S, Xu Z, Zhang C, Li Y, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Sig Transduct Target Ther. 2020;5:172.","journal-title":"Sig Transduct Target Ther"},{"key":"3930_CR28","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s13054-020-03142-8","volume":"24","author":"Z Guo","year":"2020","unstructured":"Guo Z, Chen Y, Luo X, He X, Zhang Y, Wang J. Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia. Crit Care. 2020;24:420.","journal-title":"Crit Care"},{"issue":"1","key":"3930_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s13287-020-01875-5","volume":"11","author":"L Shu","year":"2020","unstructured":"Shu L, Niu C, Li R, Huang T, Wang Y, Huang M, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020;11(1):361.","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"3930_CR30","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/sctm.20-0472","volume":"10","author":"G Lanzoni","year":"2021","unstructured":"Lanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA, Kouroupis D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1\/2a, randomized controlled trial. Stem Cells Transl Med. 2021;10(5):660\u201373.","journal-title":"Stem Cells Transl Med"},{"issue":"9","key":"3930_CR31","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/sctm.21-0046","volume":"10","author":"IH Dilogo","year":"2021","unstructured":"Dilogo IH, Aditianingsih D, Sugiarto A, Burhan E, Damayanti T, Sitompul PA, et al. Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: a randomized controlled trial. Stem Cells Transl Med. 2021;10(9):1279\u201387.","journal-title":"Stem Cells Transl Med"},{"issue":"5","key":"3930_CR32","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s00134-020-06022-5","volume":"46","author":"W Alhazzani","year":"2020","unstructured":"Alhazzani W, M\u00f8ller MH, Arabi YM, Loeb M, Gong MN, Oczkowski S, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020;46(5):854\u201387.","journal-title":"Intensive Care Med"},{"key":"3930_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2019-000420","volume":"6","author":"MJD Griffiths","year":"2019","unstructured":"Griffiths MJD, McAuley DF, Perkins GD, Barrett N, Blackwood B, Boyle A, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res. 2019;6: e000420.","journal-title":"BMJ Open Respir Res"},{"key":"3930_CR34","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1186\/s13287-021-02637-7","volume":"12","author":"M Mebarki","year":"2021","unstructured":"Mebarki M, Iglicki N, Marigny C, Abadie C, Nicolet C, Churlaud G, et al. Development of a human umbilical cord-derived mesenchymal stromal cell-based advanced therapy medicinal product to treat immune and\/or inflammatory diseases. Stem Cell Res Ther. 2021;12:571.","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"3930_CR35","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s12015-013-9492-x","volume":"10","author":"J Ge","year":"2014","unstructured":"Ge J, Guo L, Wang S, Zhang Y, Cai T, Zhao RCH, et al. The size of mesenchymal stem cells is a significant cause of vascular obstructions and stroke. Stem Cell Rev Rep. 2014;10(2):295\u2013303.","journal-title":"Stem Cell Rev Rep"},{"key":"3930_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jcyt.2016.09.010","volume":"19","author":"J Leibacher","year":"2017","unstructured":"Leibacher J, Dauber K, Ehser S, Brixner V, Kollar K, Vogel A, et al. Human mesenchymal stromal cells undergo apoptosis and fragmentation after intravenous application in immune-competent mice. Cytotherapy. 2017;19:61\u201374.","journal-title":"Cytotherapy"},{"key":"3930_CR37","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/stem.2779","volume":"36","author":"SFH de Witte","year":"2018","unstructured":"de Witte SFH, Luk F, Sierra Parraga JM, Gargesha M, Merino A, Korevaar SS, et al. Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells: the fate of MSC post infusion. Stem Cells. 2018;36:602\u201315.","journal-title":"Stem Cells"},{"issue":"5","key":"3930_CR38","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41409-017-0062-8","volume":"53","author":"SO Ciurea","year":"2018","unstructured":"Ciurea SO, Cao K, Fernandez-Vina M, Kongtim P, Malki MA, Fuchs E, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2018;53(5):521\u201334.","journal-title":"Bone Marrow Transplant"},{"key":"3930_CR39","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1161\/CIRCRESAHA.117.310712","volume":"121","author":"J Bartolucci","year":"2017","unstructured":"Bartolucci J, Verdugo FJ, Gonz\u00e1lez PL, Larrea RE, Abarzua E, Goset C, et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1\/2 randomized controlled trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). Circ Res. 2017;121:1192\u2013204.","journal-title":"Circ Res"},{"key":"3930_CR40","doi-asserted-by":"publisher","first-page":"41125","DOI":"10.1038\/srep41125","volume":"7","author":"HR Hocine","year":"2017","unstructured":"Hocine HR, Costa HE, Dam N, Giustiniani J, Palacios I, Loiseau P, et al. Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem\/progenitor cells. Sci Rep. 2017;7:41125.","journal-title":"Sci Rep"},{"key":"3930_CR41","doi-asserted-by":"publisher","first-page":"R118","DOI":"10.1186\/cc6174","volume":"11","author":"DS Karbing","year":"2007","unstructured":"Karbing DS, Kj\u00e6rgaard S, Smith BW, Espersen K, Aller\u00f8d C, Andreassen S, et al. Variation in the PaO2\/FiO2 ratio with FiO2: mathematical and experimental description, and clinical relevance. Crit Care. 2007;11:R118.","journal-title":"Crit Care"},{"issue":"18","key":"3930_CR42","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM200005043421801","volume":"342","author":"Acute Respiratory Distress Syndrome Network","year":"2000","unstructured":"Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301\u20138.","journal-title":"N Engl J Med"},{"key":"3930_CR43","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1186\/cc6777","volume":"12","author":"MF El-Khatib","year":"2008","unstructured":"El-Khatib MF, Jamaleddine GW. Clinical relevance of the PaO2\/FiO2 ratio. Crit Care. 2008;12:407.","journal-title":"Crit Care"},{"key":"3930_CR44","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1164\/rccm.200807-1136ED","volume":"178","author":"GD Rubenfeld","year":"2008","unstructured":"Rubenfeld GD, Abraham E. When is a negative phase II trial truly negative? Am J Respir Crit Care Med. 2008;178:554\u20135.","journal-title":"Am J Respir Crit Care Med"},{"key":"3930_CR45","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.148983","volume":"6","author":"KD Wick","year":"2021","unstructured":"Wick KD, Leligdowicz A, Zhuo H, Ware LB, Matthay MA. Mesenchymal stromal cells reduce evidence of lung injury in patients with ARDS. JCI Insight. 2021;6: e148983.","journal-title":"JCI Insight"},{"issue":"3","key":"3930_CR46","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s11999-014-3925-y","volume":"473","author":"CC Wyles","year":"2015","unstructured":"Wyles CC, Houdek MT, Wyles SP, Wagner ER, Behfar A, Sierra RJ. Differential cytotoxicity of corticosteroids on human mesenchymal stem cells. Clin Orthop Relat Res. 2015;473(3):1155\u201364.","journal-title":"Clin Orthop Relat Res"},{"key":"3930_CR47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/sctm.19-0202","volume":"9","author":"M Kabat","year":"2020","unstructured":"Kabat M, Bobkov I, Kumar S, Grumet M. Trends in mesenchymal stem cell clinical trials 2004\u20132018: is efficacy optimal in a narrow dose range? Stem Cells Transl Med. 2020;9:17\u201327.","journal-title":"Stem Cells Transl Med"},{"key":"3930_CR48","doi-asserted-by":"publisher","first-page":"2000858","DOI":"10.1183\/13993003.00858-2020","volume":"55","author":"M Khoury","year":"2020","unstructured":"Khoury M, Cuenca J, Cruz FF, Figueroa FE, Rocco PRM, Weiss DJ. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. Eur Respir J. 2020;55:2000858.","journal-title":"Eur Respir J"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-03930-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-022-03930-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-03930-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T21:09:25Z","timestamp":1666732165000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-022-03930-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3930"],"URL":"https:\/\/doi.org\/10.1186\/s13054-022-03930-4","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,21]]},"assertion":[{"value":"31 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The National Review Board of \u00cele-de-France III approved the trial (CNRIPH 20.03.26.39722) that was authorized by the French National Agency for Medicines and Health Products Safety (EudraCT 2020-001287-28). Written informed consent was obtained from patients or a legally designated representative.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AD declared grants or contracts from Philips, Fisher & Paykel; French Ministry of Health; Respinor; Lungspacer; consulting fees from Lungspacer, Respinor; payments or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Fisher & Paykel, Getinge, Lungspacer, Gilead, Lowenstein, Astra; support for attending meetings and\/or travel from Fisher & Paykel, Lungspacer; received equipment, materials, drugs, medical writing, gifts or other services from Lungspacer, Respinor. MF declared grants or contracts from BioM\u00e9rieux and MSD; French Ministry of Health; consulting fees from Pfizer; payments or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Fisher & Paykel and Biom\u00e9rieux; participation on a data safety monitoring board or advisory board. ONT received grants or contracts from the French National Society of Internal Medicine (SNFMI). No conflict of interests is reported for other authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}